Regencell Bioscience's 15-min chart triggers KDJ Golden Cross, bullish Marubozu pattern.

Regencell Bioscience's 15-minute chart exhibits a significant bullish trend, as evidenced by the KDJ Golden Cross and Bullish Marubozu pattern observed on October 14, 2025 at 12:30. This indicates a shift in momentum towards the upside, suggesting that the stock price has potential for further growth. The control of the market is currently in the hands of buyers, and it is likely that this bullish momentum will continue.

Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) has shown significant bullish momentum in its stock price, as evidenced by the KDJ Golden Cross and Bullish Marubozu pattern observed on October 14, 2025, at 12:30. This technical analysis suggests a shift in market sentiment, indicating potential for further price appreciation. The control of the market is currently in the hands of buyers, and it is likely that this bullish momentum will continue.

Regencell, a biotech company focusing on neurodegenerative disorders, has experienced dramatic stock price fluctuations. Its share price exploded from $1 to $84 in May and June, fueled by retail enthusiasm and speculation over an experimental cancer therapy, according to an FXLeaders report. However, the stock subsequently plummeted below $10, erasing most of its gains as momentum traders fled. Despite this volatility, the stock has shown renewed buying interest, recently climbing above $20 after consolidating near $12.

The KDJ Golden Cross and Bullish Marubozu patterns are positive indicators that suggest the stock price is likely to continue its upward trend. The KDJ Golden Cross occurs when the K-line crosses above the D-line on the KDJ indicator, indicating a bullish signal. The Bullish Marubozu pattern, observed on October 14, 2025, at 12:30, signifies a strong upward movement without any wick candles, further confirming the bullish trend.

Market watchers suggest that if the upward momentum persists, the next technical hurdle lies around the July peak near $30, which could become the bulls' near-term target. Regencell's latest rebound demonstrates that investor appetite for high-volatility biotech stories remains strong, especially when technical levels and trading momentum align.

Founded in 2014, Regencell combines traditional Chinese medicine with modern biomedical approaches. The company's origins are deeply personal, stemming from the health recovery story of COO James Chung, who attributed his improvement to an unconventional therapy. This experience inspired a research focus blending traditional Chinese medicine with modern biomedical approaches, particularly for neurodegenerative and neuropsychological disorders, according to the FXLeaders report.

Regencell's market capitalization has ballooned to around $10 billion, but the company remains lean, employing only 12 staff members. Despite its early-stage status, the company's small footprint and volatile price action continue to intrigue traders looking for dramatic upside.

In conclusion, Regencell Bioscience's latest technical indicators suggest a bullish trend, indicating potential for further price appreciation. Investors should closely monitor the company's progress and technical levels to make informed decisions.